Eli Lilly and Company (NYSE:LLY) is ranked as a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. This represents no change from the previous week and is the same ranking LLY has had from Portfolio Grader for the last month.

Eli Lilly and Company (NYSE:LLY) is one of 134 companies within the Pharmaceuticals GICS industry group, which is in turn part of the 781 company GICS Health Care sector. LLY's market value is $92.5 billion which falls in the top decile in its industry group. Currently, the stock's Portfolio Grader ranking places it 16 among the 134 companies in this industry group, placing it among the leaders; in the top quartile of the sector with a ranking of 132 among the 781 companies in the sector, and number 842 in the nearly 5,000 company Portfolio Grader universe.

The current recommendation of Buy for Eli Lilly and Company (NYSE:LLY) is the result of using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. LLY has been upgraded from a Hold to a Buy in the last week.

Eli Lilly and Company (NYSE:LLY) ranks in the top 10% of its industry group, Pharmaceuticals, and in the top decile of sector group, Health Care, with a market value of $91.7 billion. From an investment attractiveness viewpoint, LLY is ranked in the top half of the sector with a ranking of 274 among the 782 companies in the sector; Portfolio Grader's current ranking for LLY puts it 38 among the 132 companies in this industry group, placing it in the top half and number 1,727 in the 5000 company Portfolio Grader company universe.

With a $92.0 billion market value, Eli Lilly and Company (NYSE:LLY) ranks in the top decile in its industry group, Pharmaceuticals, and in the top decile of sector group, Health Care, in market value. From the viewpoint of investment attractiveness, the ranking for LLY by Portfolio Grader places it 42 among the 133 companies in this industry group, putting it in the second quartile; in the top half of the sector with a ranking of 268 among the 785 companies in the sector, and number 1,725 in the nearly 5,000 company Portfolio Grader universe.

The current recommendation of Hold for Eli Lilly and Company (NYSE:LLY) is computed using the methodology for investing of Louis Navellier and his Portfolio Grader stock evaluator. LLY has maintained this ranking for 7 months.

Currently, Eli Lilly and Company (NYSE:LLY) has a Hold using the methodology for investing of Louis Navellier and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for 7 months.

Portfolio Grader currently ranks Eli Lilly and Company (NYSE:LLY) a Hold. The methods for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier assesses and ranks nearly 5,000 stocks each week. This represents no change from the previous week and is the same ranking LLY has had from Portfolio Grader for 7 months.

Portfolio Grader currently ranks Eli Lilly and Company (NYSE:LLY) a Hold. The approach to fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week. This represents no change from the previous week and is the same ranking LLY has had from Portfolio Grader for 7 months.

Eli Lilly and Company (NYSE:LLY) is ranked as a Hold using the methods for investing of Louis Navellier and his Portfolio Grader stock evaluator. LLY has maintained this ranking for 6 months.